Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
6.55
+0.31 (4.97%)
Nov 5, 2025, 4:00 PM EST - Market closed
Design Therapeutics Stock Forecast
Stock Price Forecast
There have not been any analyst price target forecasts for Design Therapeutics in the last 12 months.
Price Target: n/a
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for Design Therapeutics.
Recommendation Trends
| Rating | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 0 | 0 | 1 | 1 | 1 | 0 |
| Hold | 4 | 4 | 3 | 3 | 3 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -38.93% | Aug 6, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $6 → $12 | Hold → Buy | Upgrades | $6 → $12 | +83.21% | May 7, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -38.93% | Mar 20, 2024 |
| Wedbush | Wedbush | Hold Reiterates $5 | Hold | Reiterates | $5 | -23.66% | Mar 20, 2024 |
| RBC Capital | RBC Capital | Hold Maintains $7 → $4 | Hold | Maintains | $7 → $4 | -38.93% | Nov 14, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.36
from -0.88
EPS Next Year
-1.24
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.37 | -0.86 | |||
| Avg | -1.36 | -1.24 | |||
| Low | -1.33 | -1.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.